It is recommended that Cabtreo be reimbursed by public drug plans for the topical treatment of acne vulgaris in patients 12 years of age and older if certain conditions are met.
It is recommended that Cabtreo be reimbursed by public drug plans for the topical treatment of acne vulgaris in patients 12 years of age and older if certain conditions are met.